Early stage concussion drug developer Oxeia Biopharmaceuticals notched an outside-the-lab win last week, signing NFL star cornerback Richard Sherman to its advisory board. Sherman, as well-known for his outspokenness as his game-saving pass defense, had already tweeted his encouragement for its work earlier in the month.
Source: NFL All-Pro Richard Sherman joins Oxeia board as it readies phase 2 concussion drug research